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To the Editor: Tentori et al.1 reported a 20% increased risk of
mortality in dialysis patients who were not taking intrave-
nous vitamin D compared to those who received vitamin D,
confirming studies showing a survival benefit in patients
administered vitamin D.2–4 However, Tentori et al. claim
there was no differences in mortality risk when comparing
the use of calcitriol (1a,25-dihydroxyvitamin D3) with
doxercalciferol (1a-hydroxyvitamin D2) and paricalcitol
(19-nor-1a,25-dihydroxyvitamin D2). Unfortunately, there
are significant limitations with their analyses, and subsequent
conclusions. The authors have taken liberty in their claim of
‘equivalency’ between doxercalciferol and paricalcitol and in
their comparison to previous studies that employed larger
databases and longer treatment periods.2–4
It is unclear if the authors understand the differences
between the various vitamin D compounds. Although both
paricalcitol and doxercalciferol are D2, whereas calcitriol is a
D3 compound, the major differentiating factor in the
activation of the vitamin D receptor (VDR) is that
paricalcitol has a modification in the A ring. In fact,
doxercalciferol is an inactive pro-hormone that has to be
converted by the liver to its active form (1a,25-dihydroxy-
vitamin D2) and it is unclear if there are differences in the
activation of the VDR by 1a,25-D3 or 1a,25-D2. Thus, it is
misleading when the authors equate paricalcitol and
doxercalciferol by referring to them collectively as D2
compounds.
Important limitations of this study include the relatively
small number of patients and the fact that the treatments
were not simultaneous but sequential and short in duration.
There were 7731 patients who received vitamin D at any time
and the median observation period was less than 10 months.
Patients who received calcitriol started sooner after initiating
dialysis, were not dosed according to KDOQI guidelines and
were started on therapy earlier in the study period than those
receiving other compounds, whereas those who received
doxercalciferol had the shortest follow-up and were started on
therapy later in the study period. Moreover, only about 50% of
the treated patients received vitamin D for more than 6 months.
The high rate of censoring was largely due to patients being
switched from one D compound to another (38%). It is likely
that the study was underpowered to show a 12–16% survival
difference between calcitriol and paricalcitol as was demon-
strated by Teng et al. after evaluation of 67 399 patients.2
On the basis of these limitations, the authors should
acknowledge that they were unable to show survival
differences among the vitamin D treatment groups in large
part because the study was underpowered and the design was
not appropriate to make a statement of equivalence. This
would be a fairer interpretation of their data than the
inappropriate claim that the major finding of the study was
the lack of a survival difference between paricalcitol and
doxercalciferol. In addition to the impact on patient care,
there is an enormous financial stake associated with the use
of these compounds. Thus, before coming to conclusions
regarding the effect of vitamin D in general and the relative
effect of different compounds in particular, appropriately
designed and powered studies are required to determine the
best practice for reducing mortality associated with chronic
kidney disease.
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We appreciate Dr Sprague’s letter1 to our article.2
Doxercalciferol undergoes hepatic conversion to its active
form (1,25-dihydroxyvitamin D2), but once activated, it is
a vitamin D2 analog.
Dialysis Clinic Inc. (DCI) is a large not-for-profit
provider. Procedural differences between DCI and for-
profit providers may influence clinical outcomes. The use
of an incident versus a prevalent cohort reduced our
sample size and the impact of potential confounders. The
crude mortality rate (deaths/100 patient years, 95%
confidence interval (CI)) was higher among patients
receiving calcitriol (19.6, 18.2–21.1) versus paricalcitol
(15.3, 13.6–16.9) (Po0.0001) or doxercalciferol (15.4,
13.6–17.1) (P¼ 0.0003). However, in our Cox models,
administration of paricalcitol and doxercalciferol versus
calcitriol was associated with a survival benefit only in the
unadjusted model and the model adjusted for demo-
graphics, reflecting our relatively small sample. Never-
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